Why Shares of Sage Therapeutics Slumped This Week
Shares of Sage Therapeutics (NASDAQ: SAGE) were down by more than 40% for the week at 11 a.m. on Friday, according to data provided by S&P Global Market Intelligence. The pharmaceutical company's stock closed last week at $36.10, then fell to a 52-week loss of $16.52 on Monday. The stock is down more than 44% this year.
The stock suffered a double whammy of news that drove it lower. First, last Friday, after the markets closed, Sage and announced that their therapy Zurzuvae (zuranolone) had been approved by the Food and Drug Administration (FDA) for postpartum depression (PPD) but not for major depressive disorder (MDD). The FDA sent a complete response letter to Sage regarding Zurzuvae's New Drug Application for its use on MDD patients, asking for more studies before approval. The problem for Sage is that roughly 600,000 women every year may have PPD symptoms, while MDD has a much larger patient population. According to the Anxiety and Depression Association of America, in 2020, roughly 14.8 million U.S. adults had at least one major depressive episode with severe impairment.
The second blow came when the company announced second-quarter earnings on Monday. Sage's revenue was reported as $2.5 million, up 66% year over year. However, the company also had a net loss of $160.3, compared to a loss of $126.3 million in the same period a year ago.
Source Fool.com
Biogen Inc. Stock
The stock is one of the favorites of our community with 50 Buy predictions and 1 Sell predictions.
With a target price of 293 € there is a positive potential of 35.33% for Biogen Inc. compared to the current price of 216.5 €.
